Literature DB >> 10731693

Functional consequences of the deletion mutation deltaGlu160 in human cardiac troponin T.

K Harada1, F Takahashi-Yanaga, R Minakami, S Morimoto, I Ohtsuki.   

Abstract

To explore the functional consequences of a deletion mutation of troponin T (DeltaGlu160) found in familial hypertrophic cardiomyopathy, the mutant human cardiac troponin T, and wild-type troponins T, I, and C were expressed in Escherichia coli and directly incorporated into isolated porcine cardiac myofibrils using our previously reported troponin exchange technique. The mutant troponin T showed a slightly reduced potency in replacing the endogenous troponin complex in myofibrils and did not affect the inhibitory action of troponin I but potentiated the neutralizing action of troponin C, suggesting that the deletion of a single amino acid, Glu-160, in the strong tropomyosin-binding region affects the tropomyosin binding affinity of the entire troponin T molecule and alters the interaction between troponin I and troponin C within ternary troponin complex in the thin filament. This mutation also increased the Ca(2+) sensitivity of the myofibrillar ATPase activity, as in the case of other mutations in troponin T with clinical phenotypes of poor prognosis similar to that of Glu160. These results provide strong evidence that the increased Ca(2+) sensitivity of cardiac myofilament is a typical functional consequence of the troponin T mutation associated with a malignant form of hypertrophic cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10731693     DOI: 10.1093/oxfordjournals.jbchem.a022603

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  16 in total

1.  Disease-causing mutations in cardiac troponin T: identification of a critical tropomyosin-binding region.

Authors:  T Palm; S Graboski; S E Hitchcock-DeGregori; N J Greenfield
Journal:  Biophys J       Date:  2001-11       Impact factor: 4.033

Review 2.  Hypertrophic cardiomyopathy: from genetics to treatment.

Authors:  Ali J Marian
Journal:  Eur J Clin Invest       Date:  2010-04       Impact factor: 4.686

3.  HCM-linked ∆160E cardiac troponin T mutation causes unique progressive structural and molecular ventricular remodeling in transgenic mice.

Authors:  Rachel K Moore; Lauren Tal Grinspan; Jesus Jimenez; Pia J Guinto; Briar Ertz-Berger; Jil C Tardiff
Journal:  J Mol Cell Cardiol       Date:  2013-02-19       Impact factor: 5.000

4.  Computational Tool to Study Perturbations in Muscle Regulation and Its Application to Heart Disease.

Authors:  Samantha K Barrick; Sarah R Clippinger; Lina Greenberg; Michael J Greenberg
Journal:  Biophys J       Date:  2019-05-07       Impact factor: 4.033

Review 5.  Moving beyond simple answers to complex disorders in sarcomeric cardiomyopathies: the role of integrated systems.

Authors:  Andrea E Deranek; Matthew M Klass; Jil C Tardiff
Journal:  Pflugers Arch       Date:  2019-03-08       Impact factor: 3.657

Review 6.  Molecular genetics and pathogenesis of hypertrophic cardiomyopathy.

Authors:  A J Marian; L Salek; S Lutucuta
Journal:  Minerva Med       Date:  2001-12       Impact factor: 4.806

7.  Allosteric effects of cardiac troponin TNT1 mutations on actomyosin binding: a novel pathogenic mechanism for hypertrophic cardiomyopathy.

Authors:  Rachel K Moore; Salwa Abdullah; Jil C Tardiff
Journal:  Arch Biochem Biophys       Date:  2014-01-28       Impact factor: 4.013

Review 8.  Experimental therapies in hypertrophic cardiomyopathy.

Authors:  Ali J Marian
Journal:  J Cardiovasc Transl Res       Date:  2009-10-01       Impact factor: 4.132

Review 9.  Increased myofilament Ca2+-sensitivity and arrhythmia susceptibility.

Authors:  Sabine Huke; Björn C Knollmann
Journal:  J Mol Cell Cardiol       Date:  2010-01-22       Impact factor: 5.000

Review 10.  TNNT1, TNNT2, and TNNT3: Isoform genes, regulation, and structure-function relationships.

Authors:  Bin Wei; J-P Jin
Journal:  Gene       Date:  2016-01-13       Impact factor: 3.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.